← TuHURA Biosciences, Inc./NV (HURA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
TuHURA Biosciences, Inc./NV (HURA)
Pharmaceutical Preparations · market cap $133M · as of 2026-07-13
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-13 (est.)
Earnings
Pipeline
1
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
TuHURA Biosciences (HURA) is a small-cap clinical-stage pharmaceutical company with 19 employees and a market cap of ~$164M. Its lead and sole pipeline asset, IFx-Hu2.0, is in Phase 3 development targeting Advanced or Metastatic Merkel Cell Carcinoma (MCC). The next major catalyst is an estimated Phase 3 interim or primary readout by March 31, 2027, rated high importance.
The catalyst path
- 2026-11-13 (est.)Earningsimp 5/10
- 2027-03-31 (est.)Phase 3 · IFx-Hu2.0imp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| IFx-Hu2.0 | Phase 3 | Advanced Or Metastatic Merkel Cell Carcinoma |
Price & technical context
3-month
-19.9%
6-month
+34.0%
12-month
-25.6%
52-wk range
$0.44–$3.15
vs 50-day MA
-11.0%
vs 200-day MA
+1.8%
Realized vol
123.8%
Max drawdown
-94.5%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for HURA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.